PTC Therapeutics (NASDAQ: PTCT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-28 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.510 | -1.780 | -0.2700 | ||||
REV | 147.060M | 148.735M | 1.675M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of PTC Therapeutics (NASDAQ: PTCT) through any online brokerage.
Other companies in PTC Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Karuna Therapeutics (NASDAQ:KRTX), Sage Therapeutics (NASDAQ:SAGE), Fate Therapeutics (NASDAQ:FATE) and Mirati Therapeutics (NASDAQ:MRTX).
The latest price target for PTC Therapeutics (NASDAQ: PTCT) was reported by RBC Capital on Thursday, June 23, 2022. The analyst firm set a price target for 46.00 expecting PTCT to rise to within 12 months (a possible 14.37% upside). 8 analyst firms have reported ratings in the last year.
The stock price for PTC Therapeutics (NASDAQ: PTCT) is $40.22 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for PTC Therapeutics.
PTC Therapeutics’s Q2 earnings are confirmed for Thursday, July 28, 2022.
There is no upcoming split for PTC Therapeutics.
PTC Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.